- X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
- X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
- X4 Pharmaceuticals Announces Proposed Underwritten Public Offering